Company profile
4TEEN4 Pharmaceuticals company profile
4TEEN4 Pharmaceuticals GmbH is a biopharmaceutical company developing Procizumab, a first in class antibody therapy targeting circulating Dipeptidyl Peptidase 3 (cDPP3), a validated biotarget for the treatment of Circulatory Shock. 4TEEN4 Pharmaceuticals GmbH developed and out-licenses a DPP3 assay, for prediction and stratification of patients in danger of entering into Circulatory Shock
Business identity
- Website
- https://4teen4.de/
- Contact email
- [email protected]
- Phone number
- +49 33 02/866 885-0
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 00011-00050 employees
- Founded
- 2013-06-13
Headquarters
- Headquarters
- Hennigsdorf, Brandenburg, Germany
- Postal code
- 16761
- Country code
- DE
- Continent
- Europe